Gritstone Oncology

Gritstone Oncology

Company profile

About

Gritstone Oncology (NASDAQ:GRTS) is a biotechnology company striving to discover, develop, and commercialize immunotherapies for cancer treatment. Their innovative approach focuses on developing personalized cancer vaccines and potent viral vectors to stimulate the immune system to recognize and destroy tumors effectively. With a range of projects spanning from pre-clinical trials to advanced stages of clinical development, Gritstone aims to tackle various cancer types, harnessing the power of genomics and bespoke immunotherapies to transform cancer treatment paradigms. Their overarching objective is to significantly improve patient outcomes by deploying unique technologies that unveil and target the unique genetic mutations of individual cancers, paving the way for more effective and tailored treatment options.

Snapshot

2015Year founded

200Employees

Emeryville, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Gritstone Oncology

GRANITE - an individualized neoantigen-based vaccine aimed at solid tumors, utilizing a patient's tumor to tailor the treatment.
SLATE - an off-the-shelf neoantigen-based vaccine targeting shared tumor-specific mutations, designed for multiple cancer types.
CORAL - a program focused on developing an mRNA vaccine for SARS-CoV-2 and its variants, leveraging neoantigen expertise to target the virus more effectively.
EDISON - a cutting-edge AI-driven platform to predict cancer-specific neoantigens, enhancing vaccine design and patient matching.
Clinical trials management, overseeing the design, recruitment, and execution of studies for their proprietary cancer vaccines and immunotherapies.
Partnerships with biotech and pharmaceutical companies for the co-development and licensing of their vaccine platforms and AI technology, expanding their reach and impact in oncology.